U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H15F3N4O3
Molecular Weight 404.3426
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOSUFLOXACIN

SMILES

NC1CCN(C1)C2=NC3=C(C=C2F)C(=O)C(=CN3C4=CC=C(F)C=C4F)C(O)=O

InChI

InChIKey=WUWFMDMBOJLQIV-UHFFFAOYSA-N
InChI=1S/C19H15F3N4O3/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29)

HIDE SMILES / InChI

Description

Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
1993 Apr
In-vitro activity of quinolones and macrolides against mycobacteria.
1994 Sep
Trovafloxacin is active against Toxoplasma gondii.
1996 Aug
Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
1996 Dec
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
1996 Nov
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.
1996 Oct
[In vitro anti-MAC activities of new quinolones in focus (2)].
1996 Sep
Quinolones alter defense reactions mediated by macrophages.
2001 Feb
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
2002 Mar
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.
2004 Apr
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
2009
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009 Dec 2
[Intractable pediatric infectious disease: examining the ability of a new drug, tosufloxacin tosilate hydrate for pediatric].
2010 Dec
[Epidemiological analysis of Streptococcus pneumoniae in Gifu prefecture].
2010 Jun
Legionella pneumophila induces cathepsin B-dependent necrotic cell death with releasing high mobility group box1 in macrophages.
2010 Nov 22
Patents

Sample Use Guides

In Vivo Use Guide
In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day. Osteomyelitis, arthritis: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 3 times a day. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day. Typhoid/paratyphoid fever: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 4 times a day for 14 days.
Route of Administration: Oral
In Vitro Use Guide
The MIC90s of tosufloxacin among the 27 isolates of macrolide-resistant Mycoplasma pneumoniae (MRMP) was 0.25 ug/ml and those among the 23 isolates of macrolide-sensitive Mycoplasma pneumoniae (MSMP) was 0.5 μg/ml.
Name Type Language
TOSUFLOXACIN
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
A 67107
Code English
ABBOTT-61827
Code English
TOSUFLOXACIN [INN]
Common Name English
ABBOTT 61827
Code English
1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 7-(3-AMINO-1-PYRROLIDINYL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-, (+/-)-
Common Name English
TOSUFLOXACIN [MI]
Common Name English
(+/-)-7-(3-AMINO-1-PYRROLIDINYL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID
Systematic Name English
TOSUFLOXACIN [MART.]
Common Name English
TOSUFLOXACIN [USAN]
Common Name English
A 61827
Code English
TOSUFLOXACIN [WHO-DD]
Common Name English
A-67107
Code English
A-61827
Code English
Code System Code Type Description
EPA CompTox
100490-36-6
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY
ChEMBL
CHEMBL273348
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY
INN
6242
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY
EVMPD
SUB11201MIG
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY
NCI_THESAURUS
C80642
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY
WIKIPEDIA
TOSUFLOXACIN
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY
CAS
100490-36-6
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY
MERCK INDEX
M10984
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY Merck Index
PUBCHEM
5517
Created by admin on Tue Mar 06 11:54:38 UTC 2018 , Edited by admin on Tue Mar 06 11:54:38 UTC 2018
PRIMARY SWITZERF